DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a

References

• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–9. doi:10.1038/387296a0. PMID:9153395.
   PubMed Web of Science ®Google Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303. doi:10.1038/387299a0. PMID:9153396.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–8. doi:10.1126/science.1092472. PMID:14704432.
   PubMed Web of Science ®Google Scholar
• Selivanova, G. Wild type p53 reactivation: From lab bench to clinic. FEBS Lett. 2014;588(16):2628–38. doi:10.1016/j.febslet.2014.03.049. PMID:24726725.
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci. 2006;103(6):1888–93. doi:10.1073/pnas.0507493103. PMID:16443686.
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene. 2008;27(40):5303–14. doi:10.1038/onc.2008.164. PMID:18521084.
   PubMed Web of Science ®Google Scholar
• Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106(9):3150–9. doi:10.1182/blood-2005-02-0553. PMID:16014563.
   PubMed Web of Science ®Google Scholar
• Shen H, Moran DM, Maki CG. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008;68(20):8260–8. doi:10.1158/0008-5472.CAN-08-1901. PMID:18922897.
   PubMed Web of Science ®Google Scholar
• Huang B, Deo D, Xia M, Vassilev LT. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res. 2009;7(9):1497–509. doi:10.1158/1541-7786.MCR-09-0144. PMID:19737973.
   PubMed Web of Science ®Google Scholar
• Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nature Rev Genet. 2012;13(5):343–57. doi:10.1038/nrg3173. PMID:22473383.
   PubMed Web of Science ®Google Scholar
• Yi X, Xiang XJ, Li XY, Jiang DS. Histone methyltransferases: novel targets for tumor and developmental defects. Am J Transl Res. 2015;7(11):2159–75. PMID:26807165.
   PubMed Web of Science ®Google Scholar
• Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491–507. doi:10.1016/j.molcel.2012.11.006. PMID:23200123.
   PubMed Web of Science ®Google Scholar
• Huang T, Lin C, Zhong LL, Zhao L, Zhang G, Lu A, Wu J, Bian Z. Targeting histone methylation for colorectal cancer. Therap Adv Gastroenterol. 2017;10(1):114–131. doi:10.1177/1756283X16671287. PMID:28286564.
   PubMed Web of Science ®Google Scholar
• Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009;8(6):1579–88. doi:10.1158/1535-7163.MCT-09-0013. PMID:19509260.
   PubMed Web of Science ®Google Scholar
• Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin (DZNep). Clin Cancer Res. 2012;18(15):4201–12. doi:10.1158/1078-0432.CCR-12-0036. PMID:22675170.
   PubMed Web of Science ®Google Scholar
• Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: BCL-1 family proteins and apoptosis. Cell Death Diff. 2014;21(2):206–15. doi:10.1038/cdd.2013.153..
   PubMed Web of Science ®Google Scholar
• Gillies LA, Kuwana T. Apoptosis regulation at the mitochondrial outer membrane. J Cell Biochem. 2014;115(4):632–40. doi:10.1002/jcb.24709. PMID:24453042.
   PubMed Web of Science ®Google Scholar
• Ow Y-LP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol. 2008;9(7):532–42. doi:10.1038/nrm2434. PMID:18568041.
   PubMed Web of Science ®Google Scholar
• Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 2015;5(5):475–87. doi:10.1158/2159-8290.CD-15-0011. PMID:25895919.
   PubMed Web of Science ®Google Scholar
• Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Diff. 2006;13(8):1256–9. doi:10.1038/sj.cdd.4401962..
   PubMed Web of Science ®Google Scholar
• Jiang M, Milner J. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev. 2003;17(7):832–7. doi:10.1101/gad.252603. PMID:12670866.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumorigenesis and cancer therapy. Cell Death Diff. 2011;18(9):1414–24. doi:10.1038/cdd.2011.17..
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. doi:10.1038/nm.3048. PMID:23291630.
   PubMed Web of Science ®Google Scholar
• Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax tranlocation. Cancer Res. 2007;67(2):782–91. doi:10.1158/0008-5472.CAN-06-3964. PMID:17234790.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–88. doi:10.1016/j.ccr.2006.10.006. PMID:17097560.
   PubMed Web of Science ®Google Scholar
• Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of Bcl-2 expression by p53 in hematopoietic cells. Oncogene. 2001;20(2):240–51. doi:10.1038/sj.onc.1204067. PMID:11313951.
   PubMed Web of Science ®Google Scholar
• Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54(8):2095–7. PMID:8174112.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res. 1994;54(12):3131–5. PMID:8205530.
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21(9):1050–63. doi:10.1101/gad.1524107. PMID:17437993.
   PubMed Web of Science ®Google Scholar
• Borchardt RT, Keller BT, Patel-Thombre U, Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J Biol Chem. 1984;259(7):4353–8. PMID:6707008.
   PubMed Web of Science ®Google Scholar
• Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther. 1998;77(2):115–34. doi:10.1016/S0163-7258(97)00089-2. PMID:9578320.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, et al. Effect of the MDM2 antagonist RG7112 on the p53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13(11):1133–40. doi:10.1016/S1470-2045(12)70474-6. PMID:23084521.
   PubMed Web of Science ®Google Scholar
• Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical overview of MDM2/X-targeted therapies. Front Oncol. 2016;6(7):1–7. PMID:26858935
   PubMedGoogle Scholar
• Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA. 2009;106(10):3964–9. doi:10.1073/pnas.0813333106. PMID:19225112.
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogselstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497–501. doi:10.1126/science.282.5393.1497. PMID:9822382.
   PubMed Web of Science ®Google Scholar